FRS2 and non-small cell lung carcinoma: Another case–control study which included 140 NSCLC patients and 140 healthy controls used a suggested panel integrating CTC level in blood and 5 mRNA biomarkers in saliva (CCNI, epidermal growth factor receptor [EGFR], FGF19, FRS2, and GREB1).